US Pre-Market SEC Filings Roundup — August 13, 2026

12-08-2026

BBB FOODS INC reported strong revenue growth of 38.7% YoY to Ps. 26,037,292 for Q2 2026, driven by a 20.0% same-store sales increase and 155 new store openings. However, the company remained unprofitable, posting a net loss of Ps. 386,336 (margin -1.5%), and operating profit declined 10.4% YoY as administrative expenses surged 95.3%. On a half-year basis, net loss widened 153.2% to Ps. 944,595, and EBITDA fell 2.2% despite a 36.2% revenue increase.

• · Gross profit margin improved 54 bps YoY to 16.8% in Q2 2026.
• · Sales expenses grew 31.4% YoY but declined 56 bps as a percentage of revenue.
• · Other income (net) fell 72.4% YoY to Ps. 16,227 in Q2 2026.
• · Financial costs increased 27.1% YoY to Ps. 482,652 in Q2 2026.
• · Income tax expense surged 77.0% YoY to Ps. 207,507 in Q2 2026.
• · Net loss margin remained flat at -1.5% in Q2 2026 vs Q2 2025.
• · For 1H 2026, operating profit declined 51.7% YoY and operating margin fell to 0.7% from 1.9%.
• · Total assets grew 20.6% to Ps. 36,815,764 as of June 30, 2026 vs December 31, 2025.
• · Total liabilities increased 16.7% to Ps. 30,811,354 over the same period.
• · Stockholders' equity rose 45.6% to Ps. 6,004,410, partly due to a primary share offering netting Ps. 1,486,855 in 1H 2026.
• · Cash and cash equivalents increased to Ps. 1,981,125 as of June 30, 2026 from Ps. 1,427,248 at year-end 2025.

12-08-2026

Neal Harmon, CEO of Angel Studios, filed a Schedule 13D/A disclosing beneficial ownership of 17,344,753 shares of common stock (11.8% of outstanding shares) as of August 5, 2026. He transferred 5,073,000 Class B shares to a noncharitable purpose trust and 3,277,536 Class B shares to estate planning trusts on June 29, 2026, preserving voting power while reducing direct ownership. Despite the transfers, Harmon retains significant voting control, representing approximately 24.7% of voting power due to the ten-to-one voting ratio of Class B shares.

• · The Amended Charter was filed with Delaware Secretary of State on June 17, 2026, allowing Class B shares transferred to Qualifying Purpose Trusts and Qualifying Estate Planning Trusts to retain their conversion rights.
• · The Angel Mission Trust is an irrevocable Delaware noncharitable purpose trust with no named beneficiaries; shares are not intended for distribution.
• · Harmon disclaims beneficial ownership of securities he does not directly control, specifically those held by family trusts and family members.
• · No other transactions in Class A or Class B common stock occurred in the 60 days prior to the filing date.
• · Harmon may receive additional securities under the Issuer's equity incentive plans, subject to board approval.

13-08-2026

Newbury Street II Acquisition Corp reported net income of $311,304 for Q2 2026 and $1,697,549 for the first six months of 2026, a significant decline from $1,685,471 and $3,370,725 in the same periods of 2025. The decrease was driven by sharply higher general and administrative costs ($1,316,359 in Q2 2026 vs $164,940 in Q2 2025) and lower interest earned on trust account securities ($1,623,762 in Q2 2026 vs $1,839,175 in Q2 2025). The company's cash position fell 49% from $772,506 at year-end to $396,294, while the accumulated deficit grew to ($6,814,409) and total liabilities increased to $7,327,605.

• · Accretion for Class A Ordinary Shares to redemption amount was $1,598,972 in Q1 2026 and $1,623,762 in Q2 2026.
• · Weighted average shares outstanding: 17,250,000 redeemable Class A and 6,866,375 non-redeemable Class A and Class B for all periods.
• · Basic and diluted net income per share was $0.01 for Q2 2026 and $0.07 for six months 2026, down from $0.07 and $0.14 in prior year periods.
• · Accrued offering costs remained at $25,000 as of both June 30, 2026 and December 31, 2025.
• · Net cash used in operating activities was $376,212 for six months 2026 versus $171,907 for six months 2025.

13-08-2026

Hyperion DeFi, Inc. reported a net income of $30.95M for Q2 2026, a sharp turnaround from a net loss of $8.69M in Q2 2025, driven primarily by large unrealized and realized gains on digital assets totaling $34.8M. Revenue grew to $357,693 from zero in the prior-year quarter, but operating expenses excluding digital asset gains remained high at $3.92M in SG&A. The company's balance sheet strengthened significantly, with total assets more than doubling to $113.1M from $51.8M at year-end 2025, though this was fueled by $17.4M in financing cash inflows and a $57.7M surge in digital asset holdings.

• · Operating cash flow remained negative at -$7.09M for H1 2026, though slightly improved from -$7.89M in H1 2025.
• · The company raised $10.5M from a direct common stock offering and $8.95M from an At-the-Market offering in H1 2026, but financing cash flow dropped 70.5% from H1 2025's $58.8M which included a $50M preferred stock private placement.
• · Digital assets surged 353.5% to $74.1M from $16.3M at year-end, while digital intangible assets grew to $25.7M from $20.6M.
• · The company recorded a $2.0M impairment loss on digital intangible assets in H1 2026.
• · Accounts payable decreased to $139,114 from $317,900, while notes payable (current portion) increased to $2.8M from $0.
• · The accumulated deficit improved to $200.8M from $240.6M, a 16.5% reduction.
• · Basic EPS swung to $1.01 from a loss of $2.50 per share in Q2 2025, but diluted shares outstanding increased 384% to 17.0M from 3.5M.
• · The company retired all 82,324 treasury shares during H1 2026.

13-08-2026

Royalty Management Holding Corp (RMCOW) reported a net income of $375,220 for Q2 2026, a significant turnaround from a net loss of $49,528 in Q2 2025, driven by a $419,714 gain on warrant fair value adjustment. However, for the first six months of 2026, the company posted a net loss of $277,138, widening from a $108,283 loss in the prior-year period, as operating losses increased and cost of revenue grew faster than revenue. Total revenue for Q2 2026 rose 38% to $1,831,814, but gross profit declined 32% to $152,878 due to a sharp rise in cost of revenue.

• · Cost of revenue for Q2 2026 was $1,678,936, up 52.4% from $1,101,994 in Q2 2025, outpacing revenue growth.
• · General and administrative expenses decreased 14% to $174,147 in Q2 2026 from $202,218 in Q2 2025.
• · Net cash used in operating activities for H1 2026 was $211,326, compared to $76,916 in H1 2025.
• · The company issued $468,600 in preferred shares and $167,270 in convertible notes during H1 2026.
• · Dividends declared totaled $37,898 in Q2 2026, consistent with prior quarters.
• · Fair value liability of public warrants increased to $877,775 as of June 30, 2026 from $682,889 at year-end 2025.

13-08-2026

Elmet Group Co. reported a net loss of $4.488M for Q2 FY26 and $4.826M for H1 FY26, compared to net income of $1.240M and $2.437M in the prior-year periods, respectively. Revenue grew 35.1% YoY in Q2 to $66.401M and 28.2% YoY in H1 to $122.408M, driven by strong top-line expansion. However, operating expenses surged, particularly general and administrative costs which rose 342.7% in Q2, leading to an operating loss of $7.628M versus a $3.246M operating income a year ago. The company completed an IPO during the quarter, raising $125.363M in net proceeds, which significantly strengthened its cash position to $66.122M from $1.759M at year-end 2025.

• · The company completed an initial public offering (IPO) during Q2 FY26, issuing 9,857,142 shares of Common Stock and raising $125.363M in net proceeds.
• · All Class A Common Stock (20,122,721 shares) and Class B Common Stock (466 shares) were converted to Common Stock in connection with the IPO.
• · General and administrative expenses surged to $17.780M in Q2 FY26 from $4.016M in Q2 FY25, a 342.7% increase, largely due to stock-based compensation of $10.090M in the quarter.
• · Research and development expenses increased 328.2% YoY to $4.321M in Q2 FY26.
• · Inventories grew 47.0% to $102.401M from $69.697M at year-end 2025, driven by a 160.8% increase in raw materials to $28.257M.
• · The company reported a net loss per share (basic and diluted) of ($0.16) for Q2 FY26 versus earnings per share of $0.06 in Q2 FY25.
• · Cash used in operating activities from continuing operations was $7.572M in H1 FY26, compared to cash provided of $9.024M in H1 FY25.
• · The company had no discontinued operations in FY26, compared to a loss from discontinued operations of $1.546M in H1 FY25.
• · Total liabilities decreased to $96.685M from $115.189M at year-end 2025, primarily due to repayment of long-term debt and related party debt.
• · The company's effective tax rate was negative in Q2 FY26 due to a $3.750M income tax benefit, compared to $0 provision in Q2 FY25.

13-08-2026

Karyopharm Therapeutics reported a net loss of $67.0M for Q2 2026, widening from a $37.3M loss in Q2 2025, driven by higher other expenses. Total revenue declined 11.8% YoY to $33.4M, while product revenue grew slightly by 3.7% to $30.8M. The company strengthened its balance sheet with $50.2M in equity proceeds, but total liabilities rose to $441.5M and the accumulated deficit expanded to $1.85B, resulting in a negative stockholders' deficit of $330.2M.

• · Cash and cash equivalents decreased to $55.0M at June 30, 2026 from $60.5M at Dec 31, 2025.
• · Total liabilities increased to $441.5M from $401.3M at year-end 2025.
• · Stockholders' deficit worsened to ($330.2M) from ($292.9M).
• · The company issued 2,994,219 common shares under the Open Market Sale Agreement and 1,030,000 shares in a private placement, raising gross proceeds of approximately $50.2M.
• · Net cash used in operating activities was $47.7M for the first six months of 2026, improving from $57.7M in the prior year period.
• · Gross product revenue for the six months ended June 30, 2026 was $79.3M compared to $78.8M in the prior year, while provisions for product revenue decreased to $19.3M from $28.1M.
• · The company recognized $11.3M of interest expense added to debt principal in H1 2026, not present in H1 2025.

13-08-2026

Mizuho Financial Group, Inc. disclosed a 5.3% beneficial ownership stake in McKinley Acquisition Corp (MKLYU) as of June 30, 2026, holding 940,027 common shares. The filing was made on Schedule 13G, indicating the shares were acquired in the ordinary course of business and not with the intent to influence control of the issuer. This passive stake by a major global financial institution represents a significant but non-controlling interest in the blank-check company.

• · Mizuho's ownership is reported on a Rule 13d-1(b) basis, meaning the stake is passive and not for control purposes.
• · The 940,027 shares are held through wholly-owned subsidiary Mizuho Securities USA LLC, with Mizuho Bank, Ltd. and Mizuho Americas LLC also named as indirect beneficial owners.
• · Exhibits A and B grant powers of attorney to Takahiro Katsura for filing future 13G amendments on behalf of Mizuho Financial Group, Mizuho Bank, Mizuho Americas, and Mizuho Securities USA.
• · Filing was made on August 13, 2026, as of the date of the change in ownership (June 30, 2026).
• · McKinley Acquisition Corp is a blank-check company (SIC 6770) incorporated in E9 (likely Cayman Islands) with its business address in Needham, MA.

13-08-2026

Cellectar Biosciences reported Q2 2026 financial results, highlighting a cash position of $34.0 million as of June 30, 2026, up from $13.2 million at year-end 2025, primarily due to a $31.7 million net offering in May 2026. The company advanced its pipeline, initiating site activation for the confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia (NDA submission planned mid-2027) and dosing first patients in a Phase 1b trial of CLR 125 in triple-negative breast cancer. However, net loss widened to $6.9 million from $5.4 million in the prior-year quarter, driven by increased R&D spending ($4.6 million vs. $2.4 million), while G&A expenses decreased to $2.6 million from $3.6 million.

• · Median duration of response (DOR) in CLOVER WaM evaluable patients was 16 months (range: 7.3-25.4 months); 20% of patients exceeded 30 months DOR.
• · Phase 3 confirmatory trial will be a comparator, randomized controlled study with approximately 100 WM patients per arm; full enrollment projected within 18-24 months of first patient.
• · NDA submission for iopofosine I 131 planned for mid-2027 under FDA Accelerated Approval Program; Breakthrough Therapy Designation allows approximate 6-month review.
• · Phase 1b CLR 125 trial in TNBC will determine recommended dose for subsequent Phase 2 trial.
• · Cash runway expected into Q2 2027.
• · Net loss per share improved to $0.57 in Q2 2026 from $3.39 in Q2 2025 due to increased share count (8.25M vs 4.24M shares outstanding).

13-08-2026

ADI Global Distribution Inc. reported record Q2 2026 net revenue of $1,286 million, up 1% YoY, driven by security, professional AV, and data communications categories. However, income from operations fell 56% to $25 million and Adjusted EBITDA declined 9% to $86 million, reflecting higher SG&A costs and unfavorable mix. The company completed its spin-off from Resideo and initiated its standalone 2026 outlook with full-year net revenue guidance of $4,950-$5,000 million.

• · Q2 2026 net revenue was a record $1,286 million, up 1% YoY, but average daily sales growth was 2% YoY with one fewer sales day.
• · Gross margin improved 50 bps to 22.7%, helped by ~$20 million in tariff refunds, but partially offset by unfavorable price/mix and higher fuel costs.
• · SG&A expenses rose $16 million to $206 million due to higher employee and facility costs.
• · Net income swung to $6 million from a net loss of $283 million in Q2 2025, largely due to the absence of a $331 million Indemnification Agreement expense.
• · Adjusted EBITDA declined 9% to $86 million, and Adjusted EBITDA margin fell to 6.7% from 7.4%.
• · First half 2026 net revenue was $2,492 million; full year 2026 guidance implies second half net revenue of $2,458-$2,508 million.
• · Full year 2026 Adjusted Standalone EBITDA guidance is $275-$295 million, implying second half of $139-$159 million.
• · Cash and cash equivalents were $131 million at July 4, 2026, plus $400 million in restricted cash; after spin-off liquidity includes $150 million cash and a $500 million undrawn revolver.
• · Long-term debt stood at $988 million at July 4, 2026, down from $1,185 million at December 31, 2025.
• · Operating cash flow was negative $76 million in the first half of 2026, compared to positive $32 million in the prior year period.
• · The residential audio-visual category declined due to a soft U.S. residential housing market.

13-08-2026

enCore Energy Corp. reported H1 2026 results with uranium deliveries up 38.6% to 485,000 lbs at a higher average price of $70.10/lb, but extraction fell 58.7% to 131,274 lbs and net loss per share widened to $0.19 from $0.16. Operating costs rose sharply to $75.54/lb delivered and $57.36/lb extracted, while total liquidity stood at $88.4M. The company is advancing permitting for new wellfields and executed a workforce reduction in July 2026 to cut costs.

• · Alta Mesa Wellfield 7 is scheduled to cease recovery in Q3-2026 due to depletion.
• · Final permits for Wellfield 8 at Alta Mesa are anticipated by end of Q1-2027.
• · Dewey Burdock received a 20-year Source Materials License renewal effective until June 2046.
• · State of South Dakota permitting for Dewey Burdock began June 15, 2026.
• · Workforce reduction executed in July 2026; savings expected from Q3 2026 onward.
• · Equity grants to directors and officers on August 17, 2026: 351,350 RSUs (1-year vest), 409,189 RSUs (3-year ratable), 461,757 PSUs (3-year performance), 101,351 stock options (3-year ratable, 5-year term).

12-08-2026

Director Zhang Shuo sold 1,501 Common Stock at $51.47 (~$77.3K). Zhang Shuo holds 23,380 shares after the transaction.

• · Director Zhang Shuo sold 1,501 Common Stock at $51.47 (~$77.3K)

12-08-2026

FITTERS Diversified Berhad filed a Schedule 13G/A with the SEC on August 12, 2026, disclosing a 0% beneficial ownership stake in Bio Green Med Solution, Inc. (BGMSP) as of June 30, 2026. The filing indicates that FITTERS Diversified Berhad does not hold any shares of BGMSP common stock, representing a complete exit from any prior position.

• · FITTERS Diversified Berhad reported 0 shares of BGMSP common stock as of June 30, 2026.
• · The filing is an amendment (SC 13G/A) to a previous Schedule 13G.
• · FITTERS Diversified Berhad is based in Kuala Lumpur, Malaysia.

12-08-2026

Chief Financial Officer Taleghani Reza bought 18,656 Class A Common Stock at $5.37 (~$100K). Taleghani Reza holds 87,621 shares after the transaction.

• · Chief Financial Officer Taleghani Reza bought 18,656 Class A Common Stock at $5.37 (~$100K)

12-08-2026

See Remarks Frangou Angeliki bought 1,062 Common Unit at $79.16 (~$84.1K). Frangou Angeliki holds 4,790,901 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · See Remarks Frangou Angeliki bought 1,050 Common Unit at $79.09 (~$83K)
• · See Remarks Frangou Angeliki bought 1,057 Common Unit at $78.40 (~$82.9K)
• · See Remarks Frangou Angeliki bought 1,062 Common Unit at $79.16 (~$84.1K)

12-08-2026

Director Wardi Teddie Benjamin acquired 4,637 Class A Common Stock. Wardi Teddie Benjamin holds 4,637 shares after the transaction.

• · Director Wardi Teddie Benjamin acquired 4,637 Class A Common Stock

12-08-2026

Ares Partners Holdco LLC and related entities filed a Schedule 13G disclosing aggregate beneficial ownership of 38,263,341 Class A shares (including shares issuable upon conversion of common units) of X-Energy, Inc., representing 12.3% of the outstanding Class A shares as of June 30, 2026. The filing details a complex ownership structure involving multiple Ares affiliates and notes that certain shares are held on behalf of third-party co-investors. No negative or flat performance metrics are present in this beneficial ownership disclosure.

• · Ares X-Energy Holdings LP directly holds 5,440,619 Class A shares and 21,762,476 Common Units.
• · Ares X-Energy Co-Invest LP directly holds 8,403,966 Class A shares solely on behalf of third-party co-investors.
• · ACIP Investments Pooling LLC - Series 31 directly holds 2,656,280 Common Units.
• · The filing is made under Rule 13d-1(d) and includes a joint filing agreement among the Reporting Persons.
• · Antony P. Ressler generally has veto authority over decisions of the board of managers of Ares Partners.

12-08-2026

See Remarks ARMEN GARO H was awarded 1,971,500 Stock Option.

• · See Remarks ARMEN GARO H was awarded 1,971,500 Stock Option

12-08-2026

Chief Technology Officer WAN XIN sold 32,372 Class A Ordinary Shares, par value $0.05 per share at $50.55 (~$1.64M). WAN XIN holds 657,540 shares after the transaction.

• · Chief Technology Officer WAN XIN sold 32,372 Class A Ordinary Shares, par value $0.05 per share at $50.55 (~$1.64M)
• · Chief Technology Officer WAN XIN sold 27,628 Class A Ordinary Shares, par value $0.05 per share at $51.40 (~$1.42M)

12-08-2026

President and CEO Kim Julie So-Young sold 89,090 American Depositary Shares at $17.10 (~$1.52M). Kim Julie So-Young holds 391,489 shares after the transaction.

• · President and CEO Kim Julie So-Young sold 89,090 American Depositary Shares at $17.10 (~$1.52M)

12-08-2026

Chief Executive Officer Tan Irving sold 6,445 Common Stock at $446.38 (~$2.88M). 7 transactions reported in total. Tan Irving holds 575,966 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · Chief Executive Officer Tan Irving sold 2,478 Common Stock at $441.48 (~$1.09M)
• · Chief Executive Officer Tan Irving sold 989 Common Stock at $442.22 (~$437K)
• · Chief Executive Officer Tan Irving sold 1,840 Common Stock at $443.35 (~$816K)
• · Chief Executive Officer Tan Irving sold 1,880 Common Stock at $444.67 (~$836K)
• · Chief Executive Officer Tan Irving sold 4,822 Common Stock at $445.45 (~$2.15M)
• · Chief Executive Officer Tan Irving sold 6,445 Common Stock at $446.38 (~$2.88M)
• · Chief Executive Officer Tan Irving sold 1,546 Common Stock at $447.18 (~$691K)

12-08-2026

Director Purcell Michael J. bought 2,000,000 Common Stock at $0.05 (~$100K). Purcell Michael J. holds 3,250,000 shares after the transaction.

• · Director Purcell Michael J. bought 2,000,000 Common Stock at $0.05 (~$100K)
• · Director Purcell Michael J. bought 2,000,000 Warrants

13-08-2026

Cyngn reported Q2 2026 revenue of $144.5K (up 328% YoY from $33.7K) and H1 2026 revenue of $249K (up 208% YoY from $80.9K), driven by EAS software subscriptions from DriveMod Tugger deployments. However, net loss widened to $6.4M in Q2 (vs $5.4M in Q2 2025) and $12.8M in H1 (vs $9.4M in H1 2025), with total costs and expenses rising 25% in Q2 and 29% in H1. The company streamlined its organization, reduced management layers, and expanded AI-assisted tools to improve efficiency, while cash and short-term investments grew to $39.7M with no debt.

• · The company streamlined the organization, reduced management layers, and expanded AI-assisted tools across engineering and business operations.
• · Cyngn engaged Baker Tilly US, LLP as its independent registered public accounting firm and Kaufman & Canoles, P.C. as outside legal counsel.
• · The FCC added foreign-made humanoid and quadruped robots to its national security Covered List, which Cyngn believes positions it favorably as a U.S.-based developer.
• · No member of the current management team has sold any shares of the company's stock.
• · The company had no debt as of June 30, 2026 and December 31, 2025.
• · H1 2026 R&D expenses increased by $2.0M (to $6.0M) primarily due to personnel costs from a change in accounting estimate related to capitalized software.
• · H1 2026 G&A expenses increased by $1.1M (to $7.8M) driven by board compensation and marketing expenses.
• · Other income (net) decreased from $1.4M in H1 2025 to $0.9M in H1 2026, mainly due to fair value measurement of warrants issued in Q1 2025.
• · Cash used in operating activities was $13.2M in H1 2026 vs $12.8M in H1 2025.
• · Financing activities provided $17.9M in H1 2026 from at-the-market equity financing and public issuance of common stock.

13-08-2026

On August 7, 2026, OnKure Therapeutics' Board approved a repricing of underwater stock options for employees and consultants, including named executive officers. The repricing covers approximately 1.7 million shares with original exercise prices ranging from $13.99 to $24.59, reset to $4.14 per share (the closing price on the effective date). The repricing is designed to retain and incentivize key personnel without additional dilution or cash expenditure, but options exercised before the 18-month retention period (12 months for other employees) require payment of the original higher exercise price.

• · Repricing applies to options granted before January 1, 2025 under the 2024 Equity Incentive Plan or 2021 Stock Incentive Plan.
• · Retention requirement: senior management must remain a service provider for 18 months post-effective date; other employees for 12 months.
• · Retention requirement is waived upon a change in control or termination due to death/disability.
• · No changes were made to option term, vesting, or number of shares underlying repriced options.
• · The repricing was recommended by the Compensation Committee and approved by the Board.

12-08-2026

Linear Minerals Corp (LINMF) filed its annual report (20-F) for the fiscal year ended March 31, 2026, reporting a net loss of $2.68 million, an improvement from the $3.31 million loss in FY2025 and the $6.64 million loss in FY2024. Total assets declined 22% to $5.63 million from $7.20 million, driven by a $0.81 million write-down of exploration assets and a $0.62 million cash burn. The company ended the year with only $330,676 in cash, down 65% from $951,807, and had negative working capital of $657,582, raising going-concern risks.

• · The company had negative working capital of $657,582 at March 31, 2026 (current liabilities of $1,130,715 exceeded current assets of $473,133).
• · Exploration and evaluation assets were written down by $1,050,482 in FY2026, similar to the $1,036,875 write-down in FY2025.
• · Flow-through share premium liability decreased from $218,207 to $15,000, resulting in a $218,207 flow-through recovery in FY2026.
• · The company raised $625,000 in FY2026 through two tranches of a non-brokered private placement (3,000,000 units at $0.05/unit in January and 6,500,000 units at $0.05/unit in February 2026).
• · On July 13, 2026, after the fiscal year end, the company completed a 6.5:1 share consolidation.
• · Marketable securities were fully liquidated during FY2026 (balance of $123,912 at March 31, 2025 reduced to $0), generating $102,233 in proceeds.
• · Investor relations expense dropped 88% YoY to $39,874 from $331,591.
• · Share-based payments declined 31.5% YoY to $90,000 from $131,314.

12-08-2026

Inflection Point Acquisition Corp. V (IPEXU) announced that the SEC declared effective the Registration Statement on Form F-4 for its business combination with GOWell Technology Limited. The definitive proxy statement/prospectus will be mailed to SPAC shareholders of record as of June 30, 2026, for a vote on the combination. The filing also notes that an extension of the business combination deadline is being sought via a separate proxy solicitation.

• · The Business Combination Agreement was entered into on October 13, 2025, and amended on December 22, 2025, and July 13, 2026.
• · The record date for shareholders to vote on the business combination and the extension is June 30, 2026.
• · The extension proxy statement was filed with the SEC on July 20, 2026.
• · SPAC's securities trade on Nasdaq: Units (IPEXU), Class A ordinary shares (IPEX), and Rights (IPEXR).

12-08-2026

SoundHound AI has proposed to acquire LivePerson Inc. in a transaction that is subject to shareholder approvals and regulatory clearances. The definitive proxy statement/prospectus was filed with the SEC on July 9, 2026, and the mailing to LivePerson stockholders began on or about the same date. The filing does not disclose any financial terms, performance metrics, or period-over-period comparisons, so no quantitative data or mixed performance indicators are available.

• · The filing is a Rule 425 communication by LivePerson in connection with SoundHound AI's proposed acquisition.
• · The proxy statement/prospectus was filed with the SEC on July 9, 2026 and mailed to LivePerson stockholders on or about the same date.
• · The transaction is subject to the satisfaction of closing conditions, including required shareholder approvals and consummation of notes restructuring transactions.
• · No financial terms of the acquisition (e.g., price per share, valuation) are disclosed in this filing.

12-08-2026

ON Semiconductor CEO Hassane El Khoury and CFO Thad Trent discussed the Synaptics acquisition at the KeyBanc Technology Leadership Forum, emphasizing that investor sentiment has improved as more stakeholders recognize Synaptics' transformation over the past five years. The deal is expected to be accretive to gross margins and cash flow positive, with $200 million in synergies targeted within 18 months and additional manufacturing and revenue synergies beyond that. Management stressed the acquisition is driven by a strong core business, not a need to offset weaknesses, and that the Astra AI-first compute platform will be funded by Synaptics' free cash flow without diverting R&D from the core.

• · The deal is expected to be accretive to ON Semi's gross margin target.
• · ON Semi plans to leverage its distribution network and thousands of customers to scale Synaptics' products, addressing a historical challenge for Synaptics.
• · Over time, ON Semi may bring some of Synaptics' non-Astra products in-house to improve margins, though this is subject to cost and CapEx considerations.
• · The $200 million synergy target is a trigger for accretion within 18 months, but additional synergies from manufacturing and revenue growth are expected beyond that timeframe.
• · Management noted that many investors were initially unfamiliar with Synaptics' transformation over the last five years, but sentiment has become more favorable as due diligence progressed.

12-08-2026

Apollomics Inc. entered into securities purchase agreements resulting in gross cash proceeds of $8,000,010 from the issuance of 533,334 Class A shares at $15.00 per share, alongside related-party transactions involving its Chairman & CEO, Hung-Wen (Howard) Chen, and an affiliate of its COO, Yi-Kuei (Alex) Chen. Included in the transactions is the automatic conversion of a $2,000,000 convertible promissory note held by Howard Chen into 166,667 Class A shares at $12.00 per share (an 80% discount to the cash subscription price). The filing does not provide any details on the company's operational performance or prior-period financial results for comparison.

• · The conversion price of $12.00 per share represents an 80% discount to the $15.00 cash subscription price.
• · Maxpro Investment Co., Ltd. (an affiliate of COO Yi-Kuei (Alex) Chen) subscribed for 20,000 Class A shares for $300,000 at $15.00 per share.
• · No operational performance metrics or period-over-period comparisons are provided in this filing.